Literature DB >> 11522189

Structural features of HIV envelope defined by antibody escape mutant analysis.

S D'Costa1, K S Slobod, R G Webster, S W White, J L Hurwitz.   

Abstract

Two neutralizing antibodies specific for the V3 sequence of HIV envelope were used to generate escape variants from the HTLV(IIIB) founder virus. The full gp120 sequence of each variant was then analyzed to identify mutations responsible for immune escape. As predicted, most escape variants harbored amino acid changes in the V3 crown sequence. However, one variant differed from its founder only within the conserved C2 region. These findings, when analyzed in conjunction with crystallographic data, suggest a new three-dimensional model for HIV envelope folding, in which the V3 loop extends across the CD4-binding face of gp120 to associate with discontinuous C2 residues. This envelope configuration may provide an effective immune defense mechanism for HIV, as the highly variable residues of the V3 loop may shield conserved amino acids pertinent to viral infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522189     DOI: 10.1089/088922201316912808

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

1.  Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.

Authors:  W M Blay; S Gnanakaran; B Foley; N A Doria-Rose; B T Korber; N L Haigwood
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 3.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 4.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 5.  Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Authors:  Julia L Hurwitz; Mattia Bonsignori
Journal:  Viral Immunol       Date:  2018-01-09       Impact factor: 2.257

6.  An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Authors:  Jennifer A Schwartz; Ilia Prado; Johnathan Misamore; Deborah Weiss; Jesse Francis; Ranajit Pal; Maria Huaman; Anthony Cristillo; George K Lewis; Robert C Gallo; Anthony L DeVico; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

7.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

8.  A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

Authors:  Michael B Zwick; Robert Kelleher; Richard Jensen; Aran F Labrijn; Meng Wang; Gerald V Quinnan; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Authors:  Priyamvada Acharya; William D Tolbert; Neelakshi Gohain; Xueji Wu; Lei Yu; Tongyun Liu; Wensheng Huang; Chih-Chin Huang; Young Do Kwon; Robert K Louder; Timothy S Luongo; Jason S McLellan; Marie Pancera; Yongping Yang; Baoshan Zhang; Robin Flinko; James S Foulke; Mohammad M Sajadi; Roberta Kamin-Lewis; James E Robinson; Loïc Martin; Peter D Kwong; Yongjun Guan; Anthony L DeVico; George K Lewis; Marzena Pazgier
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

10.  Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.

Authors:  Robert E Sealy; Bart G Jones; Sherri L Surman; Kristen Branum; Nanna M Howlett; Patricia M Flynn; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2015-11-06       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.